Heme (iron protoporphyrin IX) is the prosthetic moiety of cellular hemoproteins involved in vital cellular functions of all aerobic organisms. As such, its metabolism (synthesis and degradation) is very finely regulated to meet the prevailing cellular needs of the organism. Genetically determined enzymatic lesions in heme synthesis occur in humans, and are characteristic of the heme-deficient states, known as the porphyrias. In porphyric individuals, a variety of factors including drugs and diet frequently precipitate acute life-threatening attacks characterized by grave neuropsychiatric and abdominal symptoms. In these individuals, intravenous heme corrects the underlying biochemical abnormalities and dramatically relieves such symptoms. However, the mechanism of such heme-induced reversal remains to date obscure and enigmatic. Several mechanisms have been proposed, but substantive evidence in their support is lacking. In search of a common denominator, we examined other possible metabolic effects of acute heme deficiency. Our preliminary findings in porphyric rat models indicate that in acute heme deficiency, the activity of the hepatic hemoprotein, tryptophan pyrrolase markedly reduced. Such reduction results in substantially enhanced tryptophan uptake by the brain, and consequent stimulation of 5-hydroxytryptamine (5-HT) formation. This finding represents the very first identification of a specific CNS neurotransmitter pathway to be altered in hepatic porphyria. Proposed studies are designed to investigate whether, in fact, 5-HT is responsible for the neurological symptoms of acute hepatic porphyria. Hepatic heme is also critically required for the synthesis of cytochrome P-450, one of its most avid consumers. Since little is known about the structure-function relationships of this hepatic hemoprotein, studies are proposed to examine its structural assembly. Specifically, we will determine how critical heme is for the functional integrity of this cytochrome and whether in heme-deficient states other heme analogs could partially maintain cytochrome P-450 function. The orientation of the heme in the apocytochrome cleft will also be investigated. All of these proposed studies are expected to elucidate many heretofore unproved aspects of cytochrome P-450 structure and function.

Project Start
1980-07-01
Project End
1986-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
6
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Huang, M C; Seyer, J M; Thompson, J P et al. (1991) Genomic organization of the human procollagen alpha 1(II) collagen gene. Eur J Biochem 195:593-600
Pascoe, G A; Correia, M A (1988) Role of gastrin/pentagastrin in regulation of intestinal cytochrome P-450. Comp Biochem Physiol C 90:41-6
Krowech, G; Caldera-Munoz, P S; Straub, K et al. (1986) Morphine metabolism revisited. III. Confirmation of a novel metabolic pathway. Chem Biol Interact 58:29-40
Bornheim, L M; Parish, D W; Smith, K M et al. (1986) The influence of side chain modifications of the heme moiety on prosthetic acceptance and function of rat hepatic cytochrome P-450 and tryptophan pyrrolase. Arch Biochem Biophys 246:63-74
Decker, C; Sugiyama, K; Underwood, M et al. (1986) Inactivation of rat hepatic cytochrome P-450 by spironolactone. Biochem Biophys Res Commun 136:1162-9
Wyman, J F; Gollan, J L; Settle, W et al. (1986) Incorporation of haemoglobin haem into the rat hepatic haemoproteins tryptophan pyrrolase and cytochrome P-450. Biochem J 238:837-46
Bornheim, L M; Correia, M A (1986) Fractionation and purification of hepatic microsomal cytochrome P-450 isoenzymes from phenobarbital-pretreated rats by h.p.l.c. A convenient tool for screening of isoenzymes inactivated by allylisopropylacetamide. Biochem J 239:661-9
Litman, D A; Correia, M A (1985) Elevated brain tryptophan and enhanced 5-hydroxytryptamine turnover in acute hepatic heme deficiency: clinical implications. J Pharmacol Exp Ther 232:337-45